On-treatment change in bone turnover markers predicts 2-year bone mineral density after sequential therapy following romosozumab: a real-world cohort study.

Front Endocrinol (Lausanne) · 2026 · PMC13318748 · PMID 42388877

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

did not reach statistical significancep=0.058so close (0.05 < p ≤ 0.1)

In the bisphosphonate subgroup (n=30), a numerically similar correlation was observed (ρ=−0.350), but it did not reach statistical significance (p=0.058), likely reflecting insufficient statistical power.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.